Thursday, May 07, 2015 7:46:17 AM
Dr. Phillip Frost and Steve Rubin's OPKO HEALTH (OPK) are now investors in SVON with warrants at $1.50 per share! SEC Form 8K filed this morning.
"The net offering proceeds to the Company are expected to be approximately $1,512,226." (That's 10% of the current market cap of SVON by the way.)
"On May 6, 2015, OPKO Health, Inc. (“OPKO”), a multi-national biopharmaceutical and diagnostics company, agreed to participate in the Offering. Dr. Phillip Frost and Steve Rubin, who are members of the Company’s Board of Directors, are the Chief Executive Officer and Chairman and Executive Vice President-Administration of OPKO, respectively."
Read more:
http://www.sec.gov/Archives/edgar/data/1035354/000114420415028099/v409746_8k.htm
BOOM BOOM go Sevion Therapeutics, time to rock n roll, this stock will have a ton of action going forward now that Opko is involved. Check the chart of COCP (+200%) to see what Dr. Frost can do with small market cap stocks like SVON.
Recent ELOX News
- Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:02:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/29/2024 08:11:23 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 03/21/2024 06:20:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/14/2024 08:30:38 PM
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases • GlobeNewswire Inc. • 03/13/2024 03:42:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/25/2024 02:44:31 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/24/2024 10:11:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:11:02 PM
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:26:20 PM
- Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria • GlobeNewswire Inc. • 10/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:43 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/20/2023 05:26:02 PM
- Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 09/19/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:05:57 PM
- Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2023 09:15:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 02:14:41 PM
- Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013 • GlobeNewswire Inc. • 09/07/2023 01:00:52 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM